Cell Genesys (CEGE) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (885)	4/25/2000 1:15:00 PM
From: Mama Bear	Read Replies (2) of 1298

tuck, CEGE retained 12% of ABGX after the follow on offering. "In the first quarter of 2000, Cell Genesys received net proceeds of approximately $194 million for the sale of 966,000 shares of Abgenix common stock. The transaction was related to a secondary Abgenix offering in which a total of 3,450,000 Abgenix shares were sold with 966,000 of the shares being sold by Cell Genesys. After the transaction, Cell Genesys retains 2,426,034 shares, or approximately 12 percent of Abgenix common stock." edgar-online.com Regards, Barb

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next